<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="pola-glofit-bridge-talicel-eipe">
    <meta name="study:title" content="PF1167 - Safety and efficacy of Polatuzumab vedotin plus Glofitamab as bridging therapy prior to Talicabtagene autoleucel for relapsed/ refractory B-cell lymphoma">
    <meta name="study:fileName" content="Abstracts/POLA-GLOFIT-BRIDGE-TALICEL-EIPE-PF1167.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Polatuzumab Vedotin,ADC,Glofitamab,Bispecific antibodies,Talicabtagene autoleucel,CAR-T cell therapy,Obinutuzumab,Rituximab,Monoclonal Antibody,Fludarabine,Cyclophosphamide,Chemotherapy,Tocilizumab">

    <title>PF1167: Pola-Glofit Bridge to Tali-cel in R/R BCL (Eipe) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PF1167 - Polatuzumab + Glofitamab Bridging to Tali-cel CAR-T in R/R B-Cell Lymphoma</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim</h4>
                    <p>N=14 R/R BCL Pts (≥15y) for Tali-cel CAR-T. Aim: Evaluate safety & efficacy of Pola-Glofit bridging therapy (BT).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Pola-Glofit Bridging)</h4>
                    <p>C1: Obi/R D1, Pola D2, Glofit D8(2.5mg)/D15(10mg). Subseq: Pola+Glofit(10mg) D1. Then Tali-cel CAR-T (Flu-Cy LD).</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (Post-BT & Post-CAR-T)</h4>
                    <p>Post-BT (N=14): ORR 64%, CR 14%. Post Tali-cel (N=12): ORR 75%, CR 58%. mPFS 5.7mo, mOS 6.6mo.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Post-BT CRS 36% (all G1/2). Post Tali-cel G3/4 CRS 8%. Favorable safety, high response rates with Pola-Glofit bridge.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PF1167 - Safety and efficacy of Polatuzumab vedotin plus Glofitamab as bridging therapy prior to Talicabtagene autoleucel for relapsed/ refractory B-cell lymphoma</h1>
            <p class="abstract-sub-header">Thomas Eipe, Alok Shetty, Manju Sengar, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PF1167 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Talicabtagene autoleucel (Tali-cel), an anti-CD19 CAR-T therapy, is standard of care for R/R B-cell lymphomas (BCL) in India.</li>
                        <li>Most patients (pts) receive bridging therapy (BT), conventionally dexamethasone or radiation. Recent studies explore combination chemo and targeted agents.</li>
                        <li>A Phase Ib/II study showed complementary benefit of Glofitamab (Glofit) + Polatuzumab Vedotin (Pola) in R/R DLBCL with acceptable safety and good efficacy.</li>
                        <li>The impact of specific BT regimens like Pola-Glofit is poorly characterized.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To evaluate the safety and efficacy of using Polatuzumab Vedotin + Glofitamab (Pola-Glofit) as bridging therapy in R/R BCL patients undergoing anti-CD19 CAR-T cell therapy (Tali-cel).</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Study Type: Single-center, retrospective, real-world analysis.</li>
                        <li>Patient Population: R/R BCL pts (≥15 years) who received Pola-Glofit as BT prior to Tali-cel (Nov 2023 - Jan 2025).</li>
                        <li>Pola-Glofit Bridging Regimen (21-day cycles):
                            <ul class="list-circle list-inside ml-4">
                                <li>Cycle 1: Obinutuzumab (1000mg) or Rituximab (375mg/m²) D1, Pola (1.8mg/kg) D2, Glofit D8 (2.5mg) & D15 (10mg).</li>
                                <li>Subsequent Cycles: Pola (1.8mg/kg) D1, Glofit (10mg) D1.</li>
                            </ul>
                        </li>
                        <li>CAR-T Therapy: Single infusion of Tali-cel (target dose ≥5x10⁶/kg) after Flu-Cy conditioning. Post CAR-T maintenance allowed.</li>
                        <li>Data Cutoff: January 30, 2025.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Pola-Glofit Bridging to Tali-cel CAR-T</h3>
                        <div class="schema-enrollment">
                            <strong>R/R BCL Pts (N=14 received Pola-Glofit BT)</strong>
                            <span>Aged ≥15 years, Scheduled for Tali-cel</span>
                            <span>(Single Center, Real-World Data)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-gray-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Bridging: Polatuzumab + Glofitamab</strong>
                                <span>C1: Obi/R D1, Pola D2, Glofit D8 (step-up), D15</span>
                                <span>Subseq. Cycles: Pola D1, Glofit D1</span>
                                <span>(Median 1 cycle)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                         <div class="schema-phase-group">
                            <div class="schema-phase" style="background-color: var(--sobi-light-teal-bg);">
                                <strong>CAR-T: Talicabtagene Autoleucel</strong>
                                <span>Conditioning: Flu-Cy</span>
                                <span>Tali-cel infusion (≥5x10⁶/kg)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Safety & Efficacy of Pola-Glofit BT</span>
                           <span>Safety & Efficacy post Tali-cel</span>
                           <span>ORR, CR, DOR, PFS, OS</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (Pola-Glofit Cohort, N=14)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median Age: 55 years (range, 21-72).</li>
                        <li>Female: 57%.</li>
                        <li>Median Prior Lines of Therapy: 2 (range, 1-5).</li>
                        <li>Bulky Disease: 50%.</li>
                        <li>Bone Marrow Involvement: 21%.</li>
                        <li>Median Bridging Therapy Cycles: 1 (range, 1-3).</li>
                    </ul>
                </div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results</h2>
                    <p class="text-sm font-semibold mt-1 mb-1">Post-Bridging Therapy (Pola-Glofit, N=14):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>ORR: 64% (9/14).</li>
                        <li>CR: 14% (2/14).</li>
                        <li>SD: 1 patient.</li>
                        <li>PD: 4 patients (2 died before CAR-T).</li>
                    </ul>

                    <p class="text-sm font-semibold mt-3 mb-1">Post Tali-cel Infusion (N=12 infused):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>ORR: 75% (9/12).</li>
                        <li>CR: 58% (7/12).</li>
                        <li>Patients with PD post-BT did not respond to Tali-cel.</li>
                        <li>2 deaths post Tali-cel (1 sepsis, 1 ICANS G2 with unresolved infection).</li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">Survival (Median Follow-up: 7.8 months):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median PFS: 5.7 months (95% CI, 2.2 - 9.2).</li>
                        <li>Median OS: 6.6 months (95% CI - Not Reached).</li>
                        <li>6/9 responders remain disease-free with ongoing B-cell aplasia at data cutoff.</li>
                    </ul>
                    <div class="abstract-card mt-4">
                        <h3 class="text-md font-semibold mb-2 text-center" style="color: var(--sobi-dark-blue);">Figure 1: Survival Outcomes Post Tali-cel</h3>
                         <div class="km-plot-container zoomable-image-container">
                            <img src="Assets/Eipe_Figure1_Swimmer.png" alt="Figure 1: Swimmer plot of patient responses and outcomes" class="zoomable-image mx-auto rounded-lg shadow-md" onerror="this.onerror=null;this.src='https://placehold.co/600x400/EBF4FA/1E3A8A?text=Figure+1+Not+Available';">
                        </div>
                        <p class="text-xs text-center mt-2 italic">Figure 1: Swimmer plot showing patient response, relapse, and survival (N=12 post Tali-cel).</p>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary</h2>
                     <p class="text-sm font-semibold mt-1 mb-1">Post-Bridging Therapy (Pola-Glofit, N=14):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Most common AE: CRS (36%; Grade 1: 29%, Grade 2: 7%).</li>
                        <li>No neurological events observed.</li>
                        <li>All CRS managed with tocilizumab and supportive care.</li>
                        <li>No ICU admissions or treatment-related deaths post-BT.</li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">Post Tali-cel Infusion (N=12):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Grade 3-4 Cytopenias: All patients.</li>
                        <li>CRS: Grade 3-4 in 8% (1/12); Grade 1-2 in 50% (6/12).</li>
                        <li>ICANS: Grade 2 in 1 patient.</li>
                        <li>IEC-HS: 25% (3/12).</li>
                        <li>Hypogammaglobulinemia: 50% (6/12).</li>
                    </ul>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Pola-Glofit as bridging therapy in R/R BCL demonstrated high response rates (ORR 64%, CR 14%), even after a single cycle.</li>
                <li>These responses were often sustained following Tali-cel CAR-T infusion (Post-CAR-T ORR 75%, CR 58%).</li>
                <li>The Pola-Glofit combination showed a favorable safety profile with manageable toxicity as bridging therapy.</li>
                <li>This approach appears promising for patients awaiting CAR-T cell therapy.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>AE, Adverse Event; ASH, American Society of Hematology; BCL, B-Cell Lymphoma; BT, Bridging Therapy; CAR-T, Chimeric Antigen Receptor T-cell; CI, Confidence Interval; CR, Complete Remission; CRS, Cytokine Release Syndrome; Cy, Cyclophosphamide; D, Day; DLBCL, Diffuse Large B-Cell Lymphoma; Flu, Fludarabine; G, Grade; Glofit, Glofitamab; IEC-HS, Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome; ICANS, Immune Effector Cell-Associated Neurotoxicity Syndrome; ICU, Intensive Care Unit; IV, Intravenous; kg, Kilogram; LD, Lymphodepletion; mg, Milligram; m², Square Meter; mo, Months; NR, Not Reached; Obi, Obinutuzumab; ORR, Overall Response Rate; OS, Overall Survival; PD, Progressive Disease; PFS, Progression-Free Survival; PMBCL, Primary Mediastinal B-cell Lymphoma; Pola, Polatuzumab Vedotin; Pts, Patients; R, Rituximab; R/R, Relapsed/Refractory; SD, Stable Disease; Tali-cel, Talicabtagene autoleucel.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Eipe T, Shetty A, Sengar M, et al. Safety and efficacy of Polatuzumab vedotin plus Glofitamab as bridging therapy prior to Talicabtagene autoleucel for relapsed/ refractory B-cell lymphoma. Abstract #PF1167 presented at the European Hematology Association (EHA) Congress. 12–15 June 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PF1167 | Abstract Release: 05/14/25 | Presentation: 06/13/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>
    <script defer src="abstract_features.js"></script>
</body>
</html>